{"id":"https://openalex.org/W2587812940","doi":"https://doi.org/10.1182/blood.v106.11.940.940","title":"Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin\u2019s Lymphoma: Results of a Pilot Study.","display_name":"Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin\u2019s Lymphoma: Results of a Pilot Study.","publication_year":2005,"publication_date":"2005-11-16","ids":{"openalex":"https://openalex.org/W2587812940","doi":"https://doi.org/10.1182/blood.v106.11.940.940","mag":"2587812940"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v106.11.940.940","doi":"https://doi.org/10.1182/blood.v106.11.940.940","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v106.11.940.940","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087147482","display_name":"Gaetano Corazzelli","orcid":"https://orcid.org/0000-0002-9548-4807","observed_orcids":["https://orcid.org/0000-0002-9548-4807"]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Gaetano Corazzelli","raw_affiliation_strings":["(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016024062","display_name":"Filippo Russo","orcid":"https://orcid.org/0000-0001-8128-9878","observed_orcids":["https://orcid.org/0000-0001-8128-9878"]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Filippo Russo","raw_affiliation_strings":["(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103735331","display_name":"Gaetana Capobianco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Gaetana Capobianco","raw_affiliation_strings":["(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109072193","display_name":"Gianpaolo Marcacci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Gianpaolo Marcacci","raw_affiliation_strings":["(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006135944","display_name":"Paola Della Cioppa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paola Della Cioppa","raw_affiliation_strings":["(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033029228","display_name":"Antonio Pinto","orcid":"https://orcid.org/0000-0002-9425-9026","observed_orcids":["https://orcid.org/0000-0002-9425-9026"]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Antonio Pinto","raw_affiliation_strings":["(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Intr. by Felicetto Ferrara) 1 Hematology Oncology Unit, INT, Fondazione Pascale, IRCCS, Naples, Italy","institution_ids":["https://openalex.org/I4210141868"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210141868"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4926,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.71289961,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"106","issue":"11","first_page":"940","last_page":"940"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aggressive-lymphoma","display_name":"aggressive lymphoma","score":0.7319999933242798},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9480000138282776},{"id":"https://openalex.org/keywords/ifosfamide","display_name":"ifosfamide","score":1.0},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":1.0},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":1.0},{"id":"https://openalex.org/keywords/salvage-chemotherapy","display_name":"salvage chemotherapy","score":0.8330000042915344},{"id":"https://openalex.org/keywords/stem-cell-mobilization","display_name":"stem cell mobilization","score":0.8019999861717224},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.968999981880188},{"id":"https://openalex.org/keywords/cd20-positive-lymphoma","display_name":"CD20-positive lymphoma","score":0.7459999918937683},{"id":"https://openalex.org/keywords/diffuse-large-cell-lymphoma","display_name":"diffuse large cell lymphoma","score":0.6819999814033508},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9879999756813049},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.8360000252723694}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8286904096603394},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.7188571691513062},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.6896104216575623},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.685619592666626},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.6639460325241089},{"id":"https://openalex.org/C2777506904","wikidata":"https://www.wikidata.org/wiki/Q418560","display_name":"Ifosfamide","level":4,"score":0.6351442337036133},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.5582460761070251},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5479913949966431},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5455935597419739},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4535830616950989},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4402041435241699},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4366588592529297},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4076088070869446},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3468434810638428},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3422333598136902},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.26340949535369873},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.21963945031166077},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.15626424551010132},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.14279380440711975},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v106.11.940.940","doi":"https://doi.org/10.1182/blood.v106.11.940.940","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v106.11.940.940","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2595201510","https://openalex.org/W2339192592","https://openalex.org/W2551961320","https://openalex.org/W2241980946","https://openalex.org/W2268675197","https://openalex.org/W2487959863","https://openalex.org/W1975517926","https://openalex.org/W2966535144","https://openalex.org/W1919192850","https://openalex.org/W2582754103"],"abstract_inverted_index":{"Abstract":[0],"Objective:":[1],"In":[2,449],"this":[3,472],"pilot":[4,473],"study":[5],"we":[6],"evaluated":[7,188],"the":[8,27,49,58,179,193,200,203,286,360,388,469,495,506,510],"clinical":[9,51,514],"activity,":[10,52],"toxicity":[11],"and":[12,36,43,54,65,83,97,136,197,277,293,298,318,322,344,368,380,396,405,439,455,480,500],"mobilizing":[13],"capacity":[14],"of":[15,92,120,202,251,275,285,310,324,333,419,435,471,497],"a":[16,111,143,416],"new":[17],"short-course":[18],"(bi-weekly),":[19],"dose":[20,283],"intensive,":[21],"cytoreductive/mobilizing":[22],"salvage":[23,71],"regimen":[24,60,512],"(R-GIFOX)":[25],"combining":[26],"cross-synergistic":[28],"agents":[29],"Gemcitabine":[30],"(G),":[31],"Ifosfamide":[32],"(Ifo),":[33],"Oxaliplatin":[34],"(Ox)":[35],"Rituximab":[37],"(R),":[38],"in":[39,147,160,307,314,320,432,487,505,517],"patients":[40,75,148,208,269,375,438,488],"with":[41,169,216,337,489],"relapsed":[42,217,406,414],"refractory":[44,404],"CD20+":[45],"NHL.":[46,492],"Based":[47,467],"on":[48,110,468],"predicted":[50],"tolerability":[53],"synergy":[55],"among":[56],"drugs,":[57],"R-GIFOX":[59,118,334,475,511],"may":[61],"offer":[62],"an":[63],"effective":[64,479,498],"less":[66],"toxic":[67],"alternative":[68],"to":[69,88,349,358,385,482],"Cisplatin/ARA-C-based":[70],"regimens,":[72],"also":[73,504,516],"for":[74,79,105,182,280,295,374,402],"aged":[76,149,376],"or":[77,99,153,221],"unfit":[78],"high-dose":[80],"procedures.":[81],"Patients":[82,85],"methods:":[84],"were":[86,187,257,262,278,458],"scheduled":[87],"receive":[89],"three":[90,100,190,331],"courses":[91,102,191,261,274,289,332],"therapy":[93,276],"followed":[94],"by":[95,192],"mobilization":[96,429],"ASCT":[98],"more":[101],"if":[103],"ineligible":[104],"ASCT.":[106,443],"Therapy":[107],"was":[108,164,290,305,335,362,390,430,447,476],"delivered":[109,263],"compassionate":[112],"basis":[113],"after":[114,189,330,354],"written":[115],"informed":[116],"consent.":[117],"consisted":[119],"R":[121],"(375":[122],"mg/m2,":[123,128,133],"d":[124,129,134,140],"1),":[125],"G":[126],"(1000":[127],"2),":[130],"Ox":[131],"(130":[132],"3)":[135],"Ifo":[137,297],"(5":[138,172],"g/m2,":[139],"3),":[141],"as":[142,521],"24-hour":[144],"single":[145],"infusion":[146],"\u2264":[150,377],"65":[151,378],"years,":[152,212],"fractionated":[154],"over":[155],"3":[156,273,288,345],"days":[157],"(dd":[158],"3\u20135)":[159],"older":[161,507],"patients.":[162,508],"Treatment":[163],"given":[165],"every":[166],"two":[167],"weeks":[168],"G-CSF":[170],"support":[171],"mcg/kg/day,":[173],"dd":[174],"6\u201311;":[175],"10":[176],"mcg/kg/day":[177],"at":[178,199,271,351,415],"3rd":[180],"course":[181],"stem":[183,485],"cells":[184,486],"mobilization).":[185],"Responses":[186],"integrated":[194],"FDG-PET/IWC":[195],"criteria,":[196],"reassessed":[198],"end":[201],"entire":[204],"program.":[205],"Results:":[206],"Fourteen":[207],"(median":[209,264],"age":[210],"63":[211],"range":[213,266],"37\u201378":[214],"years)":[215],"(n":[218,224],"=":[219,225,241,247],"9)":[220],"primary":[222,403],"progressive":[223],"5)":[226],"aggressive":[227,491],"[diffuse":[228],"large":[229],"cell":[230,233,428,451,523],"(n=7),":[231],"mantle":[232,450,522],"(n=4),":[234],"follicular":[235],"G3b":[236],"(n=3)],":[237],"advanced":[238],"(stage":[239],"IV":[240],"71%),":[242],"poor":[243],"risk":[244],"(IPI":[245],"3\u20135":[246],"50%;":[248],"median":[249,417],"number":[250],"previous":[252],"therapy=2,":[253],"r":[254],"1\u20134)":[255],"NHL,":[256],"accrued.":[258],"Forty-nine":[259],"total":[260],"4,":[265],"1\u20136);":[267],"thirteen":[268],"completed":[270],"least":[272],"evaluable":[279],"response.":[281],"Actual":[282],"intensity":[284],"first":[287],"81%,":[291],"83.5%,":[292],"86.5%":[294],"G,":[296],"Ox,":[299],"respectively.":[300,326,383,408],"CTCAE":[301],"v3.0":[302],"G3/G4":[303,312],"thrombocytopenia":[304],"present":[306],"26":[308],"%":[309],"courses,":[311],"neutropenia":[313,317],"22%;":[315],"febrile":[316],"infections":[319],"8%":[321],"6%":[323],"cycles,":[325],"The":[327],"ORR":[328,361,389],"assessed":[329],"77%,":[336],"7":[338],"complete":[339],"responses":[340],"(54%;":[341],"CR=5;":[342],"CRu=2)":[343],"partial;":[346],"CRu":[347],"converted":[348],"CR":[350],"BM":[352],"biopsy":[353],"6":[355,436],"courses.":[356],"According":[357,384],"age,":[359],"67%":[363],"(4":[364],"CR,":[365,371,393,399],"2":[366,400,440,453,461],"PR)":[367,373,395,401],"80%":[369],"(3":[370],"1":[372,394,456],"years":[379],"those":[381],"older,":[382],"disease":[386],"status,":[387],"40%":[391],"(1":[392],"89%":[397],"(6":[398],"patients,":[407],"Among":[409],"CRs":[410,454],"no":[411],"patient":[412],"has":[413],"time":[418],"5":[420],"months":[421],"(range,":[422],"2+":[423],"\u2212":[424],"10+).":[425],"Effective":[426],"CD34+":[427],"obtained":[431],"4":[433],"out":[434],"eligible":[437],"already":[441],"received":[442],"Failure":[444],"free":[445],"survival":[446],"79.6%.":[448],"lymphoma":[452],"PR":[457],"obtained,":[459],"including":[460],"molecular":[462],"remissions":[463],"(BM,":[464],"PB).":[465],"Conclusions:":[466],"results":[470],"study,":[474],"feasible,":[477],"tolerable,":[478],"able":[481],"mobilize":[483],"peripheral":[484],"reccurrent":[490],"It":[493],"enabled":[494],"achievement":[496],"dose-intensities":[499],"high":[501],"response":[502],"rates":[503],"Finally,":[509],"showed":[513],"activity":[515],"\u2019difficult\u2019":[518],"histotypes":[519],"such":[520],"lymphomas.":[524]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-24T00:00:00"}